Sep 21, 2022 / 08:30PM GMT
Operator
Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to review oral GLP-1 data presented at the European Association for the Study of Diabetes 2022. Today's call is being recorded.
At this time, I would like to turn the call over to Mr. Ronen Tamir, Vice President, Investor Relations. Please go ahead, sir.
Ronen Tamir - Pfizer Inc. - VP of IR
Thank you very much, and thank you all for joining us today. We're very happy to be presenting some exciting GLP-1 clinical data to you all.
Today, we will be making forward-looking statements that are subject to substantial risks and uncertainties. And I'd just like to remind you that these forward-looking statements speak only as of the webcast's original date, and we undertake no obligation to update or revise them in the future. You can find additional information on forward-looking statements in our SEC filing, including Forms 10-Q and 10-K, under the section labeled Risk Factors and Forward-looking Information and factors that may affect future results.
Now allow me to
Pfizer Inc to Review Oral GLP-1 Data Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot